Mumbai: Physicians from Tata Memorial Hospital and the Advanced Centre for Training Research and Education in Cancer (ACTREC), in collaboration with IDRS Labs, Bangalore, have successfully developed Bharat’s first child-friendly oral suspension of the chemotherapy drug 6-mercaptopurine (6-MP), aptly named PREVALL.
This pioneering development is set to revolutionise cancer treatment, particularly in hematologic malignancies such as Acute Lymphoblastic Leukaemia (ALL), by offering a more precise and child-friendly alternative to conventional tablets.
PREVALL boasts simplicity in preparation—a mere mixing process transforms it into a 100 ml liquid, with 10mg in each milliliter. Equipped with a syringe and Press In Bottle Adapter (PIBA), it facilitates precise dosing based on the patient’s weight or body surface area. These tools not only ensure accurate dosage but also minimize the risk of spills, providing added protection to caregivers against exposure to harmful compounds.
Having received approval from Bharat’s drug regulator, CDSCO, PREVALL guarantees safety and compliance. The recent publication of the study in the scientific journal ‘Paediatric Blood and Cancer’ by Tata Memorial Centre and IDRS Labs adds to the confidence of doctors and patients in its efficacy and quality, heralding a new era in child-friendly cancer medication.